Clinical Trial Update: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin [Phase 1]

View source ↗

Summary

Phase 1 study of RO5479599 alone or with cetuximab or erlotinib in patients with metastatic or locally advanced HER3-expressing solid tumors of epithelial origi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• ERLOTINIB (Erlotinib)
• RO5479599

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 1 | Status: COMPLETED